 <h1>Ambrisentan Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ambrisentan include:</b> peripheral edema.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ambrisentan: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Embryo-fetal toxicityDo not administer ambrisentan to a pregnant female because it may cause fetal harm. Ambrisentan is very likely to produce serious birth defects if used by pregnant females, as this effect has been seen consistently when it is administered to animals.Exclude pregnancy before the initiation of treatment with ambrisentan. Females of reproductive potential must use acceptable methods of contraception during treatment with ambrisentan and for one month after treatment. Obtain monthly pregnancy tests during treatment and 1 month after discontinuation of treatment.Because of the risks of embryo-fetal toxicity, for all female patients, ambrisentan is only available through a restricted program under a Risk Evaluation and Mitigation (REMS) called the Ambrisentan REMS.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ambrisentan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ambrisentan:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>rapid weight gain</li>
<li>tingling of the hands or feet</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>fever</li>
<li>headache</li>
<li>muscle aches</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>tightness of the chest</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chest pain</li>
<li>clay colored stools</li>
<li>dark urine</li>
<li>decrease in the amount of urine</li>
<li>decreased appetite</li>
<li>dilated neck veins</li>
<li>extreme tiredness or weakness</li>
<li>irregular breathing</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>noisy, rattling breathing</li>
<li>pale skin</li>
<li>skin rash, itching</li>
<li>stomach pain or tenderness</li>
<li>troubled breathing at rest</li>
<li>troubled breathing with exertion</li>
<li>vomiting</li>
<li>yellow skin or eyes</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking ambrisentan:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>sweating</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ambrisentan may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>feeling of warmth</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ambrisentan: oral tablet</i></p><h3>Hepatic</h3><p>The cumulative incidence of hepatic transaminases elevations greater than 3 times the upper limit of normal was 3.5% with a mean exposure duration of 79.5 weeks.  The 12-week incidence was 0.8% (placebo-treated patients 2.3%).  Hepatic transaminase elevations of greater than 8 times the upper limit of normal were reported in 0.2% of patients at 12 weeks and hepatic transaminase elevations greater than 6 times the upper limit of normal were reported in 0.5% at 1-year.  An elevation of bilirubin to 2 times the upper limit of normal was reported in 1 case.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hepatic transaminase increased</p>
<p><b>Frequency not reported</b>: Autoimmune hepatitis, hepatic injury<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreases in hemoglobin and hematocrit were observed during the first few weeks of treatment and appeared to stabilize thereafter.  Mean decreases in hemoglobin were 0.8 mg/dL with marked decreases in hemoglobin (greater than 15% decrease from baseline resulting in a value below the lower limit of normal) occurring in 7% of all patients.  The frequency of a marked decrease in hemoglobin was greater with the 10 mg dose.  The mechanism involved is unknown, but does not appear to be the result of hemorrhage or hemolysis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hemoglobin decreased, anemia</p>
<p><b>Postmarketing reports</b>: Decreases in hemoglobin and hematocrit resulting in anemia requiring transfusion<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 28.4%) </p>
<p><b>Common</b> (1% to 10%): Flushing, palpitations, hypotension, right ventricular failure, chest pain, cardiac failure<sup>[Ref]</sup></p><p>The incidence of peripheral edema in younger patients was similar to placebo (14% vs 13%) while the incidence in patients 65 years or older was greater in patients receiving drug (29% vs 4%).<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasal congestion (up to 10.4%)</p>
<p><b>Common</b> (1% to 10%): Sinusitis, nasopharyngitis, rhinitis, cough, upper respiratory infection, bronchitis, dyspnea, dyspnea exacerbated, pulmonary hypertension, epistaxis<sup>[Ref]</sup></p><p>The occurrence of nasal congestion was dose-dependent.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, constipation, nausea, vomiting</p>
<p><b>Postmarketing reports</b>: Diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19.4%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, syncope </p>
<p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions included: peripheral edema, nasal congestion, sinusitis, and flushing.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, visual impairment</p>
<p><b>Postmarketing reports</b>: Visual disturbance<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia</p>
<p><b>Frequency not reported</b>: Sudden hearing loss<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about ambrisentan</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>12 Reviews</li>
<li>Drug class: agents for pulmonary hypertension</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ambrisentan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Letairis</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Pulmonary Hypertension</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ambrisentan: oral tablet</i></p><h3>Hepatic</h3><p>The cumulative incidence of hepatic transaminases elevations greater than 3 times the upper limit of normal was 3.5% with a mean exposure duration of 79.5 weeks.  The 12-week incidence was 0.8% (placebo-treated patients 2.3%).  Hepatic transaminase elevations of greater than 8 times the upper limit of normal were reported in 0.2% of patients at 12 weeks and hepatic transaminase elevations greater than 6 times the upper limit of normal were reported in 0.5% at 1-year.  An elevation of bilirubin to 2 times the upper limit of normal was reported in 1 case.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hepatic transaminase increased</p><p><b>Frequency not reported</b>: Autoimmune hepatitis, hepatic injury<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreases in hemoglobin and hematocrit were observed during the first few weeks of treatment and appeared to stabilize thereafter.  Mean decreases in hemoglobin were 0.8 mg/dL with marked decreases in hemoglobin (greater than 15% decrease from baseline resulting in a value below the lower limit of normal) occurring in 7% of all patients.  The frequency of a marked decrease in hemoglobin was greater with the 10 mg dose.  The mechanism involved is unknown, but does not appear to be the result of hemorrhage or hemolysis.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hemoglobin decreased, anemia</p><p><b>Postmarketing reports</b>: Decreases in hemoglobin and hematocrit resulting in anemia requiring transfusion<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 28.4%) </p><p><b>Common</b> (1% to 10%): Flushing, palpitations, hypotension, right ventricular failure, chest pain, cardiac failure<sup>[Ref]</sup></p><p>The incidence of peripheral edema in younger patients was similar to placebo (14% vs 13%) while the incidence in patients 65 years or older was greater in patients receiving drug (29% vs 4%).<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasal congestion (up to 10.4%)</p><p><b>Common</b> (1% to 10%): Sinusitis, nasopharyngitis, rhinitis, cough, upper respiratory infection, bronchitis, dyspnea, dyspnea exacerbated, pulmonary hypertension, epistaxis<sup>[Ref]</sup></p><p>The occurrence of nasal congestion was dose-dependent.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Abdominal pain, constipation, nausea, vomiting</p><p><b>Postmarketing reports</b>: Diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (19.4%)</p><p><b>Common</b> (1% to 10%): Dizziness, syncope </p><p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions included: peripheral edema, nasal congestion, sinusitis, and flushing.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, visual impairment</p><p><b>Postmarketing reports</b>: Visual disturbance<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue, asthenia</p><p><b>Frequency not reported</b>: Sudden hearing loss<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about ambrisentan</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>12 Reviews</li>
<li>Drug class: agents for pulmonary hypertension</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ambrisentan &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Pulmonary Hypertension</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>